Myocyte enhancer factor 2: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (8 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='1tqe' size='350' side='right' caption='Mouse HDAC9 (aquamarine) complex with myocyte-specific enhancer factor (green) and DNA (PDB entry [[1tqa]])' scene=''> | |||
==Understanding of the Recruitment of HDACs by MEF2, Based on Their Structure== | ==Understanding of the Recruitment of HDACs by MEF2, Based on Their Structure== | ||
| Line 13: | Line 13: | ||
Additionally, by looking to the <scene name='Sandbox_Reserved_1/False_dimer/2'>structure</scene> obtained by X-ray crystallography, one could also think that complexes HDAC9/MEF2/DNA dimerize ''in vivo''. During the crystallization process, two complexes were contained in the same asymmetric unit, giving such a false impression. Thus, it is important to emphasize that the biological unit would be composed only by <scene name='Sandbox_Reserved_1/Complex/5'>a monomer of HDAC9, a dimer of MEF2 and a fragment of double strand DNA</scene>[http://www.ebi.ac.uk/pdbe/pqs/pqs-bin/macmol.pl?filename=1TQE]. | Additionally, by looking to the <scene name='Sandbox_Reserved_1/False_dimer/2'>structure</scene> obtained by X-ray crystallography, one could also think that complexes HDAC9/MEF2/DNA dimerize ''in vivo''. During the crystallization process, two complexes were contained in the same asymmetric unit, giving such a false impression. Thus, it is important to emphasize that the biological unit would be composed only by <scene name='Sandbox_Reserved_1/Complex/5'>a monomer of HDAC9, a dimer of MEF2 and a fragment of double strand DNA</scene>[http://www.ebi.ac.uk/pdbe/pqs/pqs-bin/macmol.pl?filename=1TQE]. | ||
*'''MEF2A''' is a substrate for p38<ref>PMID:9858528</ref>. | |||
*'''MEF2B''' and '''MEF2D''' are potent trans-activators expressed in early myogenic lineages<ref>PMID:8669199</ref>. | |||
*'''MEF2C''' controls chondrocyte hypertrophy and bone development<ref>PMID:17336904</ref>. | |||
== Disease == | == Disease == | ||
High expression of MEF2C is observed in leukemia<ref>PMID:23435431</ref>. | High expression of MEF2C is observed in leukemia<ref>PMID:23435431</ref>. Mutations in MEF2A are associated with coronary artery disease and myocardial infraction<ref>PMID:20031581</ref>. Mutations in MEF2B are associated with non-hodgkin lymphoma<ref>PMID:26245647</ref>. | ||
==Additional Resources== | ==Additional Resources== | ||
For Additional information, See [[Transcription and RNA Processing]] | For Additional information, See [[Transcription and RNA Processing]] | ||
</StructureSection> | |||
== 3D Structures of myocyte enhancer factor 2 == | |||
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | |||
[[1egw]], [[1c7u]], [[3kov]] – hMEF2A N terminal + DNA – human<br /> | [[1egw]], [[1c7u]], [[3kov]] – hMEF2A N terminal + DNA – human<br /> | ||
[[3mu6]] – hMEF2A N terminal (mutant) + DNA <br /> | [[3mu6]] – hMEF2A N terminal (mutant) + DNA <br /> | ||
[[3p57]] – hMEF2A N terminal + DNA + histone acetyltransferase<br /> | [[3p57]] – hMEF2A N terminal + DNA + histone acetyltransferase<br /> | ||
[[6c9l]] – hMEF2B <br /> | |||
[[1n6j]] – hMEF2B N terminal + DNA + calcineurin-binding protein<br /> | [[1n6j]] – hMEF2B N terminal + DNA + calcineurin-binding protein<br /> | ||
[[1tqe]] – hMEF2B N terminal + DNA + histone deacylase 9 peptide<br /> | [[1tqe]] – hMEF2B N terminal + DNA + histone deacylase 9 peptide<br /> | ||
[[6wc5]] – hMEF2B + NKX-2.5 + DNA<br /> | |||
[[7x1n]] – hMEF2D + DNA<br /> | |||
[[5f28]] – MEF2C N terminal + focal adhesion kinase 1 - mouse<br /> | |||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | |||